Skip to content

Comparison of Huoxiang Anwei Granules and Huoxiang Anwei Powder in the Treatment of Helicobacter pylori Infection: A Randomized Controlled Clinical Study

Comparison of Huoxiang Anwei Granules and Huoxiang Anwei Powder in the Treatment of Helicobacter pylori Infection: A Randomized Controlled Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001881
Enrollment
Unknown
Registered
2025-10-11
Start date
2023-09-12
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori

Interventions

Western Medicine Group:Standard quadruple therapy course of treatment 2 weeks.
Huoxiang Anwei Granules Group:Administer Huoxiang Anwei Granules 1 bag/time 2 times/day in combination with standard quadruple therapy for a course of 2 weeks.
Huoxiang Anwei Powder Group:Administer Huoxiang Anwei San 1 dose/day in combination with standard quadruple therapy for a course of 2 weeks.

Sponsors

Shenzhen Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for refractory H. pylori infection; (2) Aged between 18 and 65; (3) Volunteer to undergo the trial, gastroscopy, HP resistance and drug sensitivity testing, and sign the informed consent form; (4) Normal cognitive function, without reading and writing ability impairment; able to actively cooperate and participate in research and investigation.

Exclusion criteria

Exclusion criteria: (1) Patients with severe lesions in major organs such as liver liver and kidneys hematopoietic system diseases and tumors; (2) Used antibiotics acid suppressants and bismuth supplements within 4 weeks prior to treatment; (3) Systemic diseases that affect digestive tract dynamics (such as hyperthyroidism diabetes chronic renal insufficiency mental and nervous system diseases etc.); (4) History of upper gastrointestinal bleeding partial gastrectomy severe gastric mucosal atrophy/intestinal metaplasia etc; (5) Pregnant or breastfeeding women who are preparing for pregnancy; (6) Individuals with a history of allergies to the drugs used in this study; (7) Patients with severe primary and mental illnesses; (8) Subjects currently participating in other clinical trials; (9) The screening period test results indicate that ALT and AST values exceed the upper limit of the normal range by 2 times and total bilirubin and BUN values exceed the upper limit of the normal range by 1.5 times.

Design outcomes

Primary

MeasureTime frame
13 C-urea breath test;

Secondary

MeasureTime frame
Improvement of TCM symptoms;Improvement in quality of life;Degree of relief of anxiety and depression;

Countries

China

Contacts

Public ContactShaoju Guo

SHENZHEN Traditional Chinese Medicine Hospital

gsj1080@163.com13923838325

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026